Geode Capital Management’s Tonix Pharmaceuticals TNXP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.31M | Buy |
313,291
+41,387
| +15% | +$637K | ﹤0.01% | 2811 |
|
|
2025
Q4 | $4.25M | Buy |
271,904
+70,970
| +35% | +$1.31M | ﹤0.01% | 2858 |
|
|
2025
Q3 | $4.86M | Buy |
200,934
+25,722
| +15% | +$955K | ﹤0.01% | 2799 |
|
|
2025
Q2 | $6.31M | Buy |
175,212
+113,175
| +182% | +$2.97M | ﹤0.01% | 2607 |
|
|
2025
Q1 | $1.11M | Buy |
62,037
+42,318
| +215% | +$858K | ﹤0.01% | 3271 |
|
|
2024
Q4 | $650K | Buy |
19,719
+18,559
| +1,600% | +$386K | ﹤0.01% | 3523 |
|
|
2024
Q3 | $17.2K | Buy |
1,160
+995
| +603% | +$40K | ﹤0.01% | 4413 |
|
|
2024
Q2 | $11.5K | Buy |
165
+40
| +32% | +$18.2K | ﹤0.01% | 4530 |
|
|
2024
Q1 | $74.2K | Buy |
125
+92
| +279% | +$99.1K | ﹤0.01% | 4241 |
|
|
2023
Q4 | $43K | Sell |
33
-6
| -15% | -$9.66K | ﹤0.01% | 4384 |
|
|
2023
Q3 | $68.8K | Buy |
39
+12
| +44% | +$43.9K | ﹤0.01% | 4344 |
|
|
2023
Q2 | $135K | Hold |
27
| – | – | ﹤0.01% | 4221 |
|
|
2023
Q1 | $315K | Buy |
27
+8
| +42% | +$137K | ﹤0.01% | 3840 |
|
|
2022
Q4 | $144K | Buy |
19
+2
| +12% | +$17.3K | ﹤0.01% | 4251 |
|
|
2022
Q3 | $183K | Buy |
17
+10
| +143% | +$245K | ﹤0.01% | 4264 |
|
|
2022
Q2 | $209K | Sell |
7
-5
| -42% | -$369K | ﹤0.01% | 4235 |
|
|
2022
Q1 | $1.75M | Buy |
12
+1
| +9% | +$153K | ﹤0.01% | 3318 |
|
|
2021
Q4 | $2.58M | Sell |
11
-1
| -8% | -$318K | ﹤0.01% | 3255 |
|
|
2021
Q3 | $4.46M | Buy |
12
+3
| +33% | +$1.46M | ﹤0.01% | 2971 |
|
|
2021
Q2 | $6.13M | Buy |
9
+4
| +80% | +$2.94M | ﹤0.01% | 2777 |
|
|
2021
Q1 | $3.71M | Buy |
5
+4
| +400% | +$3.06M | ﹤0.01% | 2931 |
|
|
2020
Q4 | $624K | Hold |
1
| – | – | ﹤0.01% | 3523 |
|
|
2020
Q3 | $602K | Buy |
+1
| New | +$606K | ﹤0.01% | 3377 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 3943 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 3892 |
|
|
2019
Q4 | – | Hold |
0
| – | -$6K | – | 4226 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 4189 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 4155 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 4050 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 4038 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 4091 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 3760 |
|
|
2017
Q2 | – | Hold |
0
| – | -$47K | – | 4109 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 3954 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 3920 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3880 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 3554 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 3587 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 3072 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 3310 |
|
Other funds holding TNXP
VCM
JHC
Geode Capital Management's TNXP Position: Q1 2026 in Review
Geode Capital Management increased its Tonix Pharmaceuticals (TNXP) stake by 15% in Q1 2026, buying an estimated $637K and bringing the position to 313,291 shares worth $4.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2811.
Geode Capital Management first reported a position in TNXP in Q3 2020 and has held it in 23 quarters since. The position peaked at $6.31M in Q2 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.
- Geode Capital Management held 313,291 shares of Tonix Pharmaceuticals worth $4.31M as of Q1 2026.
- Geode Capital Management bought 41,387 Tonix Pharmaceuticals shares in Q1 2026, an estimated $637K.
- Tonix Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2811 holding.
- Geode Capital Management first reported a position in Tonix Pharmaceuticals in Q3 2020 and has held it in 23 quarters since.
- Geode Capital Management's Tonix Pharmaceuticals position peaked at $6.31M in Q2 2025.
- 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.